ghk-cu wirkung GHK-Cu: Wirkung, Dosierung & Erfahrungen GHK-Cu

1 in 10 people aged 75+ and 1 in 20 between 65 and 74 are deficient in vitamin B12

Vitamin B12 shots are recommended for people who cannot absorb enough through food or oral supplements

If traveling with peptides, use a small cooler with ice packs

BPC-157 also has complementary effects on growth factor expression, including VEGF (vascular endothelial growth factor) and bFGF (basic fibroblast growth factor)

Weight loss by timeframe Month 1-2 (initial titration): 5-10 lbs lost Lower doses, body adapting Some appetite suppression Establishing habits Month 3-4 (dose escalation): 10-20 lbs total lost Significant appetite reduction Noticeable changes Plateau possible, keep titrating Month 5-8 (approaching maintenance dose): 20-35 lbs total lost Near or at full dose Maximum appetite suppression Consistent weekly loss (1-3 lbs) Month 9-12 (maintenance dose): 30-50 lbs total lost Full dose combination Continued steady loss Body composition improving Month 12-18 (long-term): 40-60+ lbs total lost (or 15-25% body weight) Exceptional responders: 60-80 lbs Weight stabilizing Focus shifts to maintenance Individual variation: Starting weight matters (higher = more absolute loss) Metabolism, activity level, diet affect results Some lose faster, some slower Consistency most important Comparison to semaglutide monotherapy Semaglutide 2.4mg alone (typical): 6 months: 20-30 lbs 12 months: 30-40 lbs 18 months: 35-45 lbs Average: 10-15% body weight CagriSema combination (typical): 6 months: 25-40 lbs 12 months: 40-60 lbs 18 months: 50-70+ lbs Average: 15-25% body weight Additional benefit: 50-75% more weight loss with combination Example: 240 lb person Semaglutide alone: Lose 24-36 lbs 204-216 lbs CagriSema combo: Lose 36-60 lbs 180-204 lbs Clinically significant difference See our peptides before and after results and how long do peptides take to work

Mouse Tumour Studies Some mouse experiments reported lower frequencies of particular spontaneous tumours, fewer malignant tumours or altered metastasis outcomes